ESTA Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -41.47% compared to Establishment Labs Holdings's net margin of 10.18%. Establishment Labs Holdings's return on equity of -192.37% beat Bristol-Myers Squibb's return on equity of -33.18%.

Establishment Labs Holdings has a consensus price target of --, signalling upside risk potential of 35.5%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $60.91 which suggests that it could grow by 5.45%. Given that Establishment Labs Holdings has higher upside potential than Bristol-Myers Squibb, analysts believe Establishment Labs Holdings is more attractive than Bristol-Myers Squibb.

Establishment Labs Holdings has a beta of 1.165, which suggesting that the stock is 16.452% more volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.628%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.16% to investors and pays a quarterly dividend of $0.60 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Establishment Labs Holdings quarterly revenues are $40.2M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.9B. Establishment Labs Holdings's net income of -$16.7M is lower than Bristol-Myers Squibb's net income of $1.2B. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 7.99x versus 2.47x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of -41.47% compared to Establishment Labs Holdings's net margin of --. Establishment Labs Holdings's return on equity of -192.37% beat enVVeno Medical's return on equity of --.

Establishment Labs Holdings has a consensus price target of --, signalling upside risk potential of 35.5%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 538.3%. Given that enVVeno Medical has higher upside potential than Establishment Labs Holdings, analysts believe enVVeno Medical is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 1.165, which suggesting that the stock is 16.452% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.904%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $40.2M, which are larger than enVVeno Medical quarterly revenues of --. Establishment Labs Holdings's net income of -$16.7M is lower than enVVeno Medical's net income of -$5.6M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 7.99x versus 240.51x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

Onconetix has a net margin of -41.47% compared to Establishment Labs Holdings's net margin of -940.72%. Establishment Labs Holdings's return on equity of -192.37% beat Onconetix's return on equity of -2734.11%.

Establishment Labs Holdings has a consensus price target of --, signalling upside risk potential of 35.5%. On the other hand Onconetix has an analysts' consensus of -- which suggests that it could grow by 105782.35%. Given that Onconetix has higher upside potential than Establishment Labs Holdings, analysts believe Onconetix is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 1.165, which suggesting that the stock is 16.452% more volatile than S&P 500. In comparison Onconetix has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Onconetix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Onconetix pays out -- of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $40.2M, which are larger than Onconetix quarterly revenues of $406.9K. Establishment Labs Holdings's net income of -$16.7M is lower than Onconetix's net income of -$3.8M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Onconetix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 7.99x versus 0.13x for Onconetix. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -41.47% compared to Establishment Labs Holdings's net margin of --. Establishment Labs Holdings's return on equity of -192.37% beat Cassava Sciences's return on equity of --.

Establishment Labs Holdings has a consensus price target of --, signalling upside risk potential of 35.5%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4857.27%. Given that Cassava Sciences has higher upside potential than Establishment Labs Holdings, analysts believe Cassava Sciences is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 1.165, which suggesting that the stock is 16.452% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $40.2M, which are larger than Cassava Sciences quarterly revenues of --. Establishment Labs Holdings's net income of -$16.7M is higher than Cassava Sciences's net income of -$27.9M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 7.99x versus 2.57x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.